Page 50 - Read Online
P. 50

Singh et al. Cancer Drug Resist. 2025;8:56                                       Page 15 of 20



               REFERENCES
               1.  Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2:141-60. DOI PubMed
                  PMC
               2.  Ma L, Guo H, Zhao Y, et al. Liquid biopsy in cancer current: status, challenges and future prospects. Signal Transduct Target Ther.
                  2024;9:336. DOI PubMed PMC
               3.  Huang L, Rong Y, Tang X, Yi K, Wu J, Wang F. Circular RNAs are promising biomarkers in liquid biopsy for the diagnosis of
                  non-small cell lung cancer. Front Mol Biosci. 2021;8:625722. DOI PubMed PMC
               4.  Batool SM, Yekula A, Khanna P, et al. The liquid biopsy consortium: challenges and opportunities for early cancer detection and
                  monitoring. Cell Rep Med. 2023;4:101198. DOI PubMed PMC
               5.  Wen G, Zhou T, Gu W. The potential of using blood circular RNA as liquid biopsy biomarker for human diseases. Protein Cell.
                  2021;12:911-46. DOI PubMed PMC
               6.  Zhang Y, Wang Y, Su X, Wang P, Lin W. The value of circulating circular RNA in cancer diagnosis, monitoring, prognosis, and guiding
                  treatment. Front Oncol. 2021;11:736546. DOI PubMed PMC
               7.  Wang S, Zhang K, Tan S, et al. Circular RNAs in body fluids as cancer biomarkers: the new frontier of liquid biopsies. Mol Cancer.
                  2021;20:13. DOI PubMed PMC
               8.  Babin L, Andraos E, Fuchs S, Pyronnet S, Brunet E, Meggetto F. From circRNAs to fusion circRNAs in hematological malignancies.
                  JCI Insight. 2021;6:e151513. DOI PubMed PMC
               9.  Hua J, Wang Z, Cheng X, Dai J, Zhao P. Circular RNAs modulate cancer drug resistance: advances and challenges. Cancer Drug Resist.
                  2025;8:17. DOI PubMed PMC
               10.  Wu X, Shi M, Lian Y, Zhang H. Exosomal circRNAs as promising liquid biopsy biomarkers for glioma. Front Immunol.
                  2023;14:1039084. DOI PubMed PMC
               11.  Garlapati P, Ling J, Chiao PJ, Fu J. Circular RNAs regulate cancer-related signaling pathways and serve as potential diagnostic
                  biomarkers for human cancers. Cancer Cell Int. 2021;21:317. DOI PubMed PMC
               12.  Choi SS, Kim SE, Oh SY, Ahn YH. Clinical implications of circulating circular RNAs in lung cancer. Biomedicines. 2022;10:871. DOI
                  PubMed PMC
               13.  Li F, Yang Q, He AT, Yang BB. Circular RNAs in cancer: limitations in functional studies and diagnostic potential. Semin Cancer Biol.
                  2021;75:49-61. DOI PubMed
               14.  Ghani MU, Du L, Moqbel AQ, et al. Exosomal ncRNAs in liquid biopsy: a new paradigm for early cancer diagnosis and monitoring.
                  Front Oncol. 2025;15:1615433. DOI PubMed PMC
               15.  Liu XY, Zhang Q, Guo J, et al. The role of circular RNAs in the drug resistance of cancers. Front Oncol. 2021;11:790589. DOI PubMed
                  PMC
               16.  Kundu I, Varshney S, Karnati S, Naidu S. The multifaceted roles of circular RNAs in cancer hallmarks: from mechanisms to clinical
                  implications. Mol Ther Nucleic Acids. 2024;35:102286. DOI PubMed PMC
               17.  Zhang Q, Wang W, Zhou Q, et al. Roles of circRNAs in the tumour microenvironment. Mol Cancer. 2020;19:14. DOI PubMed PMC
               18.  Liu W, Niu J, Huo Y, et al. Role of circular RNAs in cancer therapy resistance. Mol Cancer. 2025;24:55. DOI PubMed PMC
               19.  Rochow H, Franz A, Jung M, et al. Instability of circular RNAs in clinical tissue samples impairs their reliable expression analysis using
                  RT-qPCR: from the myth of their advantage as biomarkers to reality. Theranostics. 2020;10:9268-79. DOI PubMed PMC
               20.  Radanova M, Mihaylova G, Tasinov O, et al. New circulating circular RNAs with diagnostic and prognostic potential in advanced
                  colorectal cancer. Int J Mol Sci. 2021;22:13283. DOI PubMed PMC
               21.  Bersani F, Picca F, Morena D, et al. Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity. J
                  Exp Clin Cancer Res. 2023;42:120. DOI PubMed PMC
               22.  Roy S, Kanda M, Nomura S, et al. Diagnostic efficacy of circular RNAs as noninvasive, liquid biopsy biomarkers for early detection of
                  gastric cancer. Mol Cancer. 2022;21:42. DOI PubMed PMC
               23.  Lu S, Liang Y, Li L, et al. Inferring circRNA-drug sensitivity associations via dual hierarchical attention networks and multiple kernel
                  fusion. BMC Genomics. 2023;24:796. DOI PubMed PMC
               24.  Pisignano G, Michael DC, Visal TH, Pirlog R, Ladomery M, Calin GA. Going circular: history, present, and future of circRNAs in
                  cancer. Oncogene. 2023;42:2783-800. DOI PubMed PMC
               25.  Wilusz JE. Circular RNAs: unexpected outputs of many protein-coding genes. RNA Biol. 2017;14:1007-17. DOI PubMed PMC
               26.  Liu X, Zhang Y, Zhou S, Dain L, Mei L, Zhu G. Circular RNA: an emerging frontier in RNA therapeutic targets, RNA therapeutics, and
                  mRNA vaccines. J Control Release. 2022;348:84-94. DOI PubMed PMC
               27.  Nielsen AF, Bindereif A, Bozzoni I, et al. Best practice standards for circular RNA research. Nat Methods. 2022;19:1208-20. DOI
                  PubMed PMC
               28.  Li Q, Wang Y, Wu S, et al. CircACC1 regulates assembly and activation of AMPK complex under metabolic stress. Cell Metab.
                  2019;30:157-73.e7. DOI PubMed            43
   45   46   47   48   49   50   51   52   53   54   55